Europe accuses drug makers of padding healthcare costs
The European Union has accused drug companies of adding billions of dollars to healthcare costs by delaying or blocking the sale of less expensive generic medicines. Patients and healthcare systems in Europe would have saved at least 3 billion euros, or $3.8 billion, from 2000 to 2007—or shaved 5% off the medical bills—if companies had let generics into the market sooner, said Neelie Kroes, the European competition commissioner.
- How Medical Debt Forgiveness Benefits Hospitals
- Leapfrog Hospital Safety Scores 'Depressing'
- Patient Harm Data to Remain on Medicare's Hospital Compare Site
- Quiet ORs Better for Patient Safety
- Tavenner Confirmed as CMS Administrator
- Building a Better Healthcare Board
- Healthcare Leaders Sound Off on Organized Labor
- Esther Dyson's Population Health Dream
- CMS Seeks to 'Rapidly Reduce' Medicare Spending with $1B in Grants
- Rural Healthcare Can Entice the Best and Brightest